Global Tuberculosis Drug Market Overview:
Tuberculosis remains a global public health concern. According to the World Health Organization, in 2017, the annual incidence of Tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection 87,000 cases per year. The TB treatment drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. About one third of the worlds's population is suffering with latent tuberculosis, people infected with mycobacterium infection have a 10% risk to fall ill with tuberculosis, however people with compromised immunity such as HIV, diabetes and tobacco addiction are at a higher risk to get tuberculosis. TB is second to HIV as it is the leading infectious killer of the adults worldwide. Apart from its health consequences, there are many economic impact of the disease which is staggering, making TB a major contributor to poverty. Some of the players profiled in the study are Johnson & Johnson (United States), Lupin Limited (India), Pfizer Inc. (United States), Eli Lilly and Company (United States), Labatec Pharma SA (Jordan), Mylan N.V (United States), Sanofi S.A (France), Sandoz S.A (Germany), Novartis International AG (India), Macleods Pharmaceuticals (India) and Otsuka Pharmaceutical Co.Ltd. (Japan).
On the basis of geography, the market of Tuberculosis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospital will boost the Tuberculosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Testing, the sub-segment i.e. TB skin test (TST) will boost the Tuberculosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Increasing Prevalence of Tuberculosis
- Government Initiatives to Control the Proliferation of Tuberculosis
- Increasing Government and Non-government Initiatives i.e. DOTS to Eradicate Tuberculosis
- Promising Pipeline for the Treatment of Tuberculosis.
- Lack of Awareness Regarding Tuberculosis in Emerging Economies
- High-Cost Factor Associated With the Treatment of Tuberculosis May Hamper the Global Tuberculosis Treatment Drugs market.
- Extensive Awareness Campaigns and Initiatives by Various Governments to Curb the Risk of Tuberculosis
- Inability to Identify the Initial Symptoms of Tuberculosis
The market is fragmented by numerous players. R&D, M&A, product launch are the key strategy adopted in the global tuberculosis diagnosis and treatment market. These players are collaborating with each other for the growth and improvement of the Tuberculosis Drugs market. For instance, In 2017, Johnson & Johnson entered into a partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to accelerate the discovery of a novel treatment for tuberculosis.
Target Audience:Tuberculosis Drugs Manufacturers, Traders/Retailers/Suppliers/Distributors, Government & Regulatory Agencies, Potential Investors, Health Care Facilities and Downstream Vendors
Major Objectives Focused through this Study To define, describe, and forecast the Global Tuberculosis Drug market on the basis of product [First-line Anti-TB Drugs and Second-line Anti-TB Drugs] , application [Active TB and Latent TB], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Tuberculosis Drug market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Tuberculosis Drug industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Tuberculosis Drug market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.